
CryoPort (CYRX) Stock Forecast & Price Target
CryoPort (CYRX) Analyst Ratings
Bulls say
CryoPort Inc. reported total revenue of $44 million, reflecting a 15% year-over-year growth on a constant currency basis, indicating consistent demand for its integrated temperature-controlled supply chain solutions within the life sciences industry. The company is witnessing a robust increase in gene therapy programs across various stages of development, particularly in oncology and rare diseases, which is expected to enhance its commercial revenue and clinical trial activities moving forward. As the market gains confidence in cell and gene therapies, CryoPort is positioned to continue benefiting from the upward trajectory of approved therapies and those in the development pipeline.
Bears say
The analysis of CryoPort's financial outlook indicates concerns rooted in declining funding for start-ups in the life sciences sector, which may adversely affect the company's growth trajectory. Although Life Sciences Services revenue showed a year-over-year increase, the slowdown in growth rate and an adjusted EBITDA margin that remains negative and below consensus expectations highlight potential profitability challenges. Furthermore, the anticipated decrease in demand for key products such as MVE freezers, along with a bearish outlook on earnings per share for 2026, bolsters the case for a cautious view on CryoPort's future performance.
This aggregate rating is based on analysts' research of CryoPort and is not a guaranteed prediction by Public.com or investment advice.
CryoPort (CYRX) Analyst Forecast & Price Prediction
Start investing in CryoPort (CYRX)
Order type
Buy in
Order amount
Est. shares
0 shares